Neurvati Neurosciences Enhances Leadership to Propel GRIN Therapeutics' Expansion

Neurvati Neurosciences Optimizes Leadership for Strategic Growth

In a significant move to enhance its growth trajectory, Neurvati Neurosciences has appointed Dr. J. Michael Ryan as the new Chief Medical Officer. Alongside this appointment, Anne-Marie Li-Kwai-Cheung has been promoted to Chief Development Officer, and Elliott Ruiz to Chief Financial Officer. These appointments position Neurvati's affiliate, GRIN Therapeutics, to advance its pivotal clinical studies and expand its neuroscience development platform.

Expanding the Leadership Team

Neurvati's latest appointments come at a crucial juncture for GRIN Therapeutics. The company is currently executing the globally pivotal Phase 3 Beeline study of radiprodil, an investigational drug intended for treating GRIN-related neurodevelopmental disorder (GRIN-NDD). Alongside this, GRIN is progressing its Phase 1b/2a Astroscape study that involves patients with conditions such as focal cortical dysplasia type II and tuberous sclerosis complex.

“We are entering an exciting phase as we execute our global Phase 3 program and strive to deliver transformative medications to patients with severe neurological disorders,” said Bruce Leuchter, the CEO of Neurvati Neurosciences. “With the addition of Michael and promotions for Anne-Marie and Elliott, we have a complementary executive team focused on enhancing our medical and enterprise capabilities.”

Dr. J. Michael Ryan: Chief Medical Officer

Dr. Ryan joins the team with a wealth of experience, covering over 25 years in neuroscience drug development across various sectors, including academia and major pharmaceutical companies. His previous position as Co-Founder and Chief Medical Officer at Aliada Therapeutics saw him lead successful clinical development initiatives until the company's acquisition by AbbVie.

As CMO, Dr. Ryan will play an integral role in guiding clinical strategies and ensuring the execution of the Beeline study, while fostering the development of GRIN Therapeutics’ expanding neuroscience portfolio.

Anne-Marie Li-Kwai-Cheung: Chief Development Officer

Anne-Marie’s promotion to Chief Development Officer, effective March 2026, recognizes her exemplary leadership in preparing GRIN Therapeutics for its Phase 3 execution. She has been pivotal in shaping the global development strategy and establishing necessary capabilities that have led to the successful initiation of the Beeline study.

Leuchter has praised Anne-Marie for her strategic mindset and operational excellence, highlighting her significant role in driving GRIN Therapeutics' growth.

Elliott Ruiz: Chief Financial Officer

Elliott’s promotion reflects his essential role in building financial and operational foundations in both Neurvati and GRIN Therapeutics. Since joining in 2022, his strategic approach has fortified the companies’ leadership and prepared them for forthcoming clinical programs while exploring future growth opportunities.

Leuchter commended Elliott for his contributions that extend beyond finance, confirming his status as an exceptional leader within the organization.

Future Prospects for GRIN Therapeutics

GRIN Therapeutics aims to bring transformative therapies to patients grappling with neurodevelopmental disorders. The company reported promising results from the Phase 1b/2a Honeycomb Trial, which assesses radiprodil for GRIN-NDD. Following this success, the company is set to proceed with the global Phase 3 Beeline trial.

Under the guidance of the newly established leadership team, Neurvati and GRIN Therapeutics are well-positioned to navigate the complexities of drug development, addressing significant challenges and advancing new therapies for patients with neurological conditions.

In conclusion, Neurvati's strategic appointments represent a vital step in its mission to innovate within the neuroscience space. By harnessing their collective experience, the leadership team at GRIN Therapeutics aims to enhance its clinical delivery and broaden its impact on patients and families globally.

For more information about Neurvati Neurosciences and GRIN Therapeutics, visit their official web portal.